Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Revenue (2020 - 2025)

Historic Revenue for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $15000.0.

  • Lyell Immunopharma's Revenue fell 5588.24% to $15000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $41000.0, marking a year-over-year decrease of 3492.06%. This contributed to the annual value of $61000.0 for FY2024, which is 5307.69% down from last year.
  • Lyell Immunopharma's Revenue amounted to $15000.0 in Q3 2025, which was down 5588.24% from $8000.0 recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Revenue peaked at $48.4 million during Q4 2022, and registered a low of $3000.0 during Q3 2022.
  • Moreover, its 5-year median value for Revenue was $27000.0 (2023), whereas its average is $5.0 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Revenue skyrocketed by 161459.96% in 2022, and later crashed by 9997.31% in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Revenue stood at $2.8 million in 2021, then skyrocketed by 1614.6% to $48.4 million in 2022, then crashed by 99.97% to $13000.0 in 2023, then dropped by 15.38% to $11000.0 in 2024, then skyrocketed by 36.36% to $15000.0 in 2025.
  • Its Revenue stands at $15000.0 for Q3 2025, versus $8000.0 for Q2 2025 and $7000.0 for Q1 2025.